Clayton, Dubilier & Rice, LLC
Long book
$536.5M
Q1 2026
Positions
2
Top-10 weight
100%
concentration
Last quarter
+68.4%
SPY +14.8%
Turnover
67%
of book per quarter
Strategy in plain words
auto-generated from filingsClayton, Dubilier & Rice, LLC is a diversified fundamental manager, specialised in consumer_discretionary (94% of the long book), running a $536.5M US long book across 2 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: RESIDEO TECHNOLOGIES INC, AGILON HEALTH INC.
Over the last 8 quarters its long book ran on average 10pp per quarter ahead of the S&P 500, beating the index in 4 of 8 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-9.5%
Q2 2024
+14.1%
Q3 2024
-7.1%
Q4 2024
-29.7%
Q2 2025
+95.7%
Q3 2025
-18.7%
Q4 2025
-4.0%
Q1 2026
+68.4%
Sector allocation
Consumer discretionary 94%
Healthcare 6%
Long book by quarter
What does Clayton, Dubilier own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 8, 2026 | 2 | $536.5M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 9, 2026 | 2 | $595.0M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 3, 2025 | 2 | $676.7M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Jul 28, 2025 | 2 | $357.3M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 9, 2025 | 2 | $435.8M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 3, 2025 | 3 | $192.6M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 1, 2024 | 4 | $401.6M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 1, 2024 | 4 | $661.9M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | Apr 26, 2024 | 4 | $618.7M | canonical | SEC ↗ |